Zentiva Announces Voluntary Purchase Offer for APONTIS PHARMA

Zentiva has revealed plans to launch a voluntary public purchase offer for APONTIS PHARMA, with an investment agreement now signed. Zentiva will offer EUR 10.00 per share, marking a 52.9% premium over APONTIS PHARMA's closing share price on October 15, 2024. A share sale agreement with Paragon, the primary shareholder of APONTIS PHARMA, has secured Zentiva a 37.5% stake.

The transaction is valued at EUR 85 million, with a minimum acceptance threshold set at 65% of shares. The deal is slated for completion by the end of Q4 2024 or early 2025, subject to regulatory approvals. APONTIS PHARMA's delisting will follow the completion of this offer as per the investment agreement. The offer document will be accessible by October 27, 2024, initiating a four-week acceptance period for shareholders.